↓ Skip to main content

Endocannabinoids

Overview of attention for book
Attention for Chapter 14: Endocannabinoids
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)

Mentioned by

twitter
4 tweeters
facebook
9 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
48 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Endocannabinoids
Chapter number 14
Book title
Endocannabinoids
Published in
Handbook of experimental pharmacology, January 2015
DOI 10.1007/978-3-319-20825-1_14
Pubmed ID
Book ISBNs
978-3-31-920824-4, 978-3-31-920825-1
Authors

O'Sullivan, Saoirse Elizabeth, Saoirse Elizabeth O’Sullivan, O’Sullivan, Saoirse Elizabeth

Editors

Roger G. Pertwee

Abstract

The endocannabinoid system is widely distributed throughout the cardiovascular system. Endocannabinoids play a minimal role in the regulation of cardiovascular function in normal conditions, but are altered in most cardiovascular disorders. In shock, endocannabinoids released within blood mediate the associated hypotension through CB1 activation. In hypertension, there is evidence for changes in the expression of CB1, and CB1 antagonism reduces blood pressure in obese hypertensive and diabetic patients. The endocannabinoid system is also upregulated in cardiac pathologies. This is likely to be cardioprotective, via CB2 and CB1 (lesser extent). In the vasculature, endocannabinoids cause vasorelaxation through activation of multiple target sites, inhibition of calcium channels, activation of potassium channels, NO production and the release of vasoactive substances. Changes in the expression or function of any of these pathways alter the vascular effect of endocannabinoids. Endocannabinoids have positive (CB2) and negative effects (CB1) on the progression of atherosclerosis. However, any negative effects of CB1 may not be consequential, as chronic CB1 antagonism in large scale human trials was not associated with significant reductions in atheroma. In neurovascular disorders such as stroke, endocannabinoids are upregulated and protective, involving activation of CB1, CB2, TRPV1 and PPARα. Although most of this evidence is from preclinical studies, it seems likely that cannabinoid-based therapies could be beneficial in a range of cardiovascular disorders.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 4%
Unknown 46 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 17%
Other 7 15%
Researcher 6 13%
Student > Ph. D. Student 6 13%
Student > Doctoral Student 5 10%
Other 8 17%
Unknown 8 17%
Readers by discipline Count As %
Medicine and Dentistry 15 31%
Agricultural and Biological Sciences 6 13%
Biochemistry, Genetics and Molecular Biology 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 5 10%
Nursing and Health Professions 2 4%
Other 7 15%
Unknown 8 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2017.
All research outputs
#3,371,622
of 14,536,182 outputs
Outputs from Handbook of experimental pharmacology
#109
of 443 outputs
Outputs of similar age
#65,681
of 263,736 outputs
Outputs of similar age from Handbook of experimental pharmacology
#2
of 3 outputs
Altmetric has tracked 14,536,182 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 443 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,736 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.